Editas Medicine (EDIT) Accumulated Depreciation & Amortization (2016 - 2025)
Editas Medicine (EDIT) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $27.7 million as the latest value for Q1 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $27.7 million in Q1 2025 year-over-year; TTM through Mar 2025 was $27.7 million, a N/A change, with the full-year FY2024 number at $31.6 million, up 20.52% from a year prior.
- Accumulated Depreciation & Amortization was $27.7 million for Q1 2025 at Editas Medicine, down from $31.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $31.6 million in Q4 2024 to a low of $12.0 million in Q1 2021.
- A 5-year average of $23.4 million and a median of $24.1 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: soared 39.77% in 2021, then rose 20.52% in 2024.
- Editas Medicine's Accumulated Depreciation & Amortization stood at $15.5 million in 2021, then skyrocketed by 38.81% to $21.5 million in 2022, then increased by 21.99% to $26.3 million in 2023, then grew by 20.52% to $31.6 million in 2024, then decreased by 12.58% to $27.7 million in 2025.
- Per Business Quant, the three most recent readings for EDIT's Accumulated Depreciation & Amortization are $27.7 million (Q1 2025), $31.6 million (Q4 2024), and $30.5 million (Q3 2024).